The Application of EU Competition Law in the Pharmaceutical Sector: The Case of Parallel Trade
Lazaros Grigorios Grigoriadis
Aristotle University of Thessaloniki
January 24, 2013
European Business Law Review, Vol. 25, No. 1, 2014, pp. 141-201
Parallel trade traditionally enjoys a significant protection from European Institutions, in the belief that it fosters competition and encourages trade. However, pharmaceutical companies claim that this form of competition undermines their incentive to innovate and threatens the competitiveness of the European pharmaceutical sector. This Article analyses a) the arguments put forward in favour of and against the freedom of parallel trade of pharmaceuticals between the EU Member States and b) the case-law relating to parallel trade of pharmaceuticals developed by the EU courts and more specifically by the Court of Justice (“CJ”) (former Court Justice of the European Communities/“ECJ”)and by the General Court (“GC”) (former Court of First Instance of the European Communities/“CFI”) in the light of the EU competition law (Articles 101-102 of the TFEU).
Keywords: Competition, EU Law, Pharmaceuticals, Parallel Trade
JEL Classification: L4, K21, K33Accepted Paper Series
Date posted: January 25, 2013 ; Last revised: February 4, 2014
© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo4 in 0.641 seconds